Literature DB >> 20678043

Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality.

Philip N Sambrook1, Jiang S Chen, Judy M Simpson, Lyn M March.   

Abstract

OBJECTIVE: To examine the impact of a national current affairs television program about the association between osteonecrosis of the jaw and bisphosphonates on subsequent prescription use, fractures and deaths. DESIGN AND
SETTING: National Pharmaceutical Benefits Scheme prescription data for 9 months after the television program were used to estimate the impact of reduced bisphosphonate use on fractures and mortality. MAIN OUTCOME MEASURES: Prescription rates, fractures and deaths.
RESULTS: The estimated reduction of 29 633 in the number of bisphosphonate prescriptions may have resulted in 70 hip fractures, 60 other fractures and 14 deaths that would otherwise have been prevented over the 9-month period of the study.
CONCLUSION: Although it is important for patients to be informed of the risks of medication, media coverage that does not present a balanced view has the potential to do more harm than good.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20678043     DOI: 10.5694/j.1326-5377.2010.tb03835.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  15 in total

Review 1.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

2.  The effect of two doses of dried plum on bone density and bone biomarkers in osteopenic postmenopausal women: a randomized, controlled trial.

Authors:  S Hooshmand; M Kern; D Metti; P Shamloufard; S C Chai; S A Johnson; M E Payton; B H Arjmandi
Journal:  Osteoporos Int       Date:  2016-02-22       Impact factor: 4.507

3.  Hip fracture trends in the United States, 2002 to 2015.

Authors:  E Michael Lewiecki; N C Wright; J R Curtis; E Siris; R F Gagel; K G Saag; A J Singer; P M Steven; R A Adler
Journal:  Osteoporos Int       Date:  2017-12-27       Impact factor: 4.507

Review 4.  Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

5.  The role of risk communication in the care of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Curr Osteoporos Rep       Date:  2011-09       Impact factor: 5.096

6.  Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.

Authors:  K N Hayes; J K Ban; G Athanasiadis; A M Burden; S M Cadarette
Journal:  Osteoporos Int       Date:  2019-07-17       Impact factor: 4.507

Review 7.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

Review 8.  Adverse effects of media reports on the treatment of osteoporosis.

Authors:  Cristiana Cipriani; Jessica Pepe; Salvatore Minisola; E Michael Lewiecki
Journal:  J Endocrinol Invest       Date:  2018-05-14       Impact factor: 4.256

9.  Impact of a change in physician reimbursement on bone mineral density testing in Ontario, Canada: a population-based study.

Authors:  Susan Jaglal; Gillian Hawker; Ruth Croxford; Cathy Cameron; Anne-Marie Schott; Sarah Munce; Sonya Allin
Journal:  CMAJ Open       Date:  2014-03-31

10.  Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary.

Authors:  Alex Fisher; Jodie Martin; Wichat Srikusalanukul; Michael Davis
Journal:  Clin Interv Aging       Date:  2010-11-19       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.